KvantifyBooth 520A new approach to drug discovery with Kvantify
At Kvantify, we are developing a computational drug discovery platform to help biotech and pharmaceutical companies improve the quality of the compounds they test in the lab by leveraging proprietary, high-speed, accurate physics-based methods. We apply our bespoke algorithms and cheminformatics expertise to optimise our customers' drug discovery pipeline.
From the early Hit-to-Lead phase to the late Lead Optimisation phase, we help companies reduce their number of high-quality candidates from thousands to a handful.
This year, we launched a tool called "Koffee", which, in less than 10 minutes, predicts and ranks small molecules according to their unbinding kinetics, or k_off rates, an important metric impacting dosage and selectivity, which there currently is no time or cost-efficient way to predict. Koffee achieves this without compromising on accuracy while being orders of magnitudes faster.
Next-gen methods - binding affinity for everyone with physics-based high-throughput methods
At BiotechX, we will present our platform's next evolution with a novel physics-based method for binding affinity. Our CEO will be in the Quantum Pharma stage on Thursday, October 10th, at 12:05 - to present our latest advancements for physics-based drug discovery methods.
Our ground-breaking solutions enable pharmaceutical and biotech companies to iterate smarter, save time and money, and derisk the drug discovery process. We are currently looking for clients who can take advantage of our help in optimising the kinetic profile of their small-molecule compounds before they get to the lab.
About Kvantify
Kvantify is a pioneering life science and quantum software company based in Denmark. Our mission is to solve the toughest challenges in life sciences and beyond, with a strong focus on drug discovery. Kvantify delivers pioneering solutions and services based on computational excellence that provide tangible value for life sciences companies today.
